Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for hard-to-treat leukemia: drug combo aims to prevent relapse

NCT ID NCT07304011

First seen Jan 05, 2026 · Last updated May 26, 2026 · Updated 25 times

Summary

This study tests a two-step treatment for adults with a specific type of acute myeloid leukemia (AML) that has a mutation in the IDH1 gene. First, patients receive a combination of two drugs (olutasidenib and azacitidine) to control the cancer. Then, they continue on a maintenance drug (olutasidenib) to try to keep the leukemia from coming back. The goal is to see if this approach works better than current options for patients who have already been treated with another standard therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.